211 related articles for article (PubMed ID: 38049318)
1. [Clinical characteristics and prognosis of patients with therapy-related myelodysplastic syndrome and acute myeloid leukemia arising from malignant tumors].
Xu XS; Ding H; Zhang X; Liao Y; Li H; Liu QY; Liu JZ; Zhang L; Huang J; Gong YP; Ma HB; Xiang B; Dai Y; Hou L; Shuai X; Niu T; Wu Y
Zhonghua Xue Ye Xue Za Zhi; 2023 Sep; 44(9):742-748. PubMed ID: 38049318
[No Abstract] [Full Text] [Related]
2. [Therapy-related myeloid neoplasms after successful treatment for acute promyelocytic leukemia: a report of four cases and literature review].
Wang Z; Xu MZ; Chen YF; Xue F; Zhang L; Hu YM; Li CW; Li SZ; Wang JX; Mi YC
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1008-1014. PubMed ID: 32023731
[No Abstract] [Full Text] [Related]
3. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.
Bello C; Yu D; Komrokji RS; Zhu W; Wetzstein GA; List AF; Lancet JE
Cancer; 2011 Apr; 117(7):1463-9. PubMed ID: 21425147
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
5. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
6. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
7. Secondary clonal cytogenetic abnormalities following successful treatment of acute promyelocytic leukemia.
Batzios C; Hayes LA; He SZ; Quach H; McQuilten ZK; Wall M; Campbell LJ
Am J Hematol; 2009 Nov; 84(11):715-9. PubMed ID: 19806661
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and Safety of Decitabine Combined with Modified EIAG Regimen in the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome].
Mao JP; Xue LG; Zhu YX; Jia T; Wang Y; Miao L; Wei JF; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):338-343. PubMed ID: 37096503
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem.
Latagliata R; Petti MC; Fenu S; Mancini M; Spiriti MA; Breccia M; Brunetti GA; Avvisati G; Lo Coco F; Mandelli F
Blood; 2002 Feb; 99(3):822-4. PubMed ID: 11806982
[TBL] [Abstract][Full Text] [Related]
10. [Clinical Analysis of Elderly Patients with AML/High-Risk MDS].
Xu WY; Wang F; Liu L; Ren XH; Liu PP; Zhang H; Zheng L; Zhang SS; Xu YR; Guo ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1311-1317. PubMed ID: 36208228
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Jabbour E; Garcia-Manero G; Cortes J; Ravandi F; Plunkett W; Gandhi V; Faderl S; O'Brien S; Borthakur G; Kadia T; Burger J; Konopleva M; Brandt M; Huang X; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):244-51. PubMed ID: 22534616
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
13. [Analysis of the clinical characteristics of acute myeloid leukemia related to the treatment of hematological and solid tumors].
Jiao Y; Jiang YH; Liu B; Mi RH; Bi LJ; Xu QX
Zhonghua Zhong Liu Za Zhi; 2024 Jan; 46(1):86-95. PubMed ID: 38246784
[No Abstract] [Full Text] [Related]
14. Conventional chemotherapy for acute myeloid leukemia: a Brazilian experience.
Pagnano KB; Traina F; Takahashi T; Oliveira GB; Rossini MS; Lorand-Metze I; Vigorito AC; Miranda EC; De Souza CA
Sao Paulo Med J; 2000 Nov; 118(6):173-8. PubMed ID: 11120548
[TBL] [Abstract][Full Text] [Related]
15. [Survival and Prognosis of Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes Transformed from Myelodysplastic Syndrome].
Shang LM; Chen HJ; Liu Y; Cao Y; Li F; Guo YT; Dong WM; Lin Y; Gu WY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):347-354. PubMed ID: 38660835
[TBL] [Abstract][Full Text] [Related]
16. Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia.
Fleischmann M; Schnetzke U; Frietsch JJ; Sayer HG; Schrenk K; Hammersen J; Glaser A; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1481-1492. PubMed ID: 34297206
[TBL] [Abstract][Full Text] [Related]
17. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of acute myeloid leukemia with myelodysplasia-related changes: A retrospective analysis in a cohort of Chinese patients.
Xu XQ; Wang JM; Gao L; Qiu HY; Chen L; Jia L; Hu XX; Yang JM; Ni X; Chen J; Lü SQ; Zhang WP; Song XM
Am J Hematol; 2014 Sep; 89(9):874-81. PubMed ID: 24861848
[TBL] [Abstract][Full Text] [Related]
19. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation.
Yalniz FF; Greenbaum U; Pasvolsky O; Milton DR; Kanagal-Shamanna R; Ramdial J; Srour S; Mehta R; Alousi A; Popat UR; Nieto Y; Kebriaei P; Al-Atrash G; Oran B; Hosing C; Ahmed S; Champlin RE; Shpall EJ; Qazilbash MH; Bashir Q
Transplant Cell Ther; 2024 Feb; 30(2):205.e1-205.e12. PubMed ID: 37437764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
